Hansa Biopharma Logo

Hansa Biopharma

HNSA | ST

Overview

Corporate Details

ISIN(s):
SE0002148817 (+1 more)
LEI:
549300LLEO25ZJJ3NT91
Country:
Sweden
Address:
Box 785, 220 07 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes innovative immunomodulating therapies for rare immunological diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology, which targets and inactivates immunoglobulin G (IgG) antibodies to inhibit harmful immune responses. This technology enables life-saving procedures, such as kidney transplantation for highly sensitized patients, and is being developed to treat a range of acute IgG-mediated autoimmune conditions. Key products include the enzyme imilfidase. The company's strategy involves drug discovery, development, commercialization, and partnerships to address significant unmet medical needs in transplantation and autoimmunity.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Hansa Biopharma. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-07 07:00
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Hansa Biopharma AB (publ)
Swedish 295.0 KB
2025-08-07 07:00
Pre-Annual General Meeting Information
Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)
English 283.6 KB
2025-08-01 21:15
Legal Proceedings Report
Hansa Biopharma announces supportive data from treatment with imlifidase prior …
English 246.4 KB
2025-08-01 21:15
Regulatory News Service
Hansa Biopharma tillkännager bekräftande resultat från behandling med imlifidas…
Swedish 232.9 KB
2025-07-17 07:00
Interim Report
Swedish 1.6 MB
2025-07-17 07:00
Interim Report
English 1.4 MB
2025-07-01 22:04
Major Shareholding Notification
Swedish 9.8 KB
2025-07-01 14:59
Major Shareholding Notification
Swedish 9.5 KB
2025-06-30 07:00
Share Issue/Capital Change
Hansa Biopharma: Ökning av antalet aktier och röster
Swedish 208.0 KB
2025-06-30 07:00
Share Issue/Capital Change
Hansa Biopharma: Increase in number of shares and votes
English 204.6 KB
2025-06-25 16:00
Post-Annual General Meeting Information
Kommuniké från årsstämma i Hansa Biopharma AB (publ)
Swedish 231.8 KB
2025-06-25 16:00
Post-Annual General Meeting Information
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
English 247.2 KB
2025-06-25 11:25
Major Shareholding Notification
Swedish 11.6 KB
2025-06-19 01:21
Share Issue/Capital Change
Hansa Biopharma has carried out a directed cash share issue of approx. mSEK 232…
English 327.9 KB
2025-06-19 01:21
Share Issue/Capital Change
Hansa Biopharma har genomfört en riktad kontantemission om ca 232 miljoner kron…
Swedish 324.2 KB

Automate Your Workflow. Get a real-time feed of all Hansa Biopharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Hansa Biopharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-06-17 Anne Säfström Lanner Other Sell 10,487 443,285.49 SEK
2024-06-17 Sören Tulstrup Other Sell 9,199 388,841.73 SEK
2024-06-17 Sören Tulstrup Other Buy 35,200 N/A
2022-07-19 Peter Nicklin Other Buy 14,500 1,032,192.68 SEK
2022-06-17 Christian Kjellman Other Buy 6,915 345,680.85 SEK
2022-06-17 Donato Spota Other Sell 4,638 231,853.62 SEK
2022-06-17 Christian Kjellman Other Sell 4,002 200,059.98 SEK
2022-06-17 Sören Tulstrup Other Sell 3,925 196,210.75 SEK
2022-06-17 Sören Tulstrup Other Buy 3,925 196,210.75 SEK
2022-06-17 Anne Säfström Lanner Other Sell 2,685 134,223.15 SEK

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK